Polaris Group (TPE:6550)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
29.30
+0.05 (0.17%)
Nov 21, 2025, 1:35 PM CST
0.17%
Market Cap22.57B
Revenue (ttm)70.83M
Net Income (ttm)-3.01B
Shares Out770.43M
EPS (ttm)-3.93
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume618,121
Average Volume664,670
Open29.25
Previous Close29.25
Day's Range28.80 - 29.70
52-Week Range26.35 - 55.20
Beta0.11
RSI23.99
Earnings DateNov 11, 2025

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Grand Cayman. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 165
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6550
Full Company Profile

Financial Performance

In 2024, Polaris Group's revenue was 107.00 million, an increase of 1330.29% compared to the previous year's 7.48 million. Losses were -2.50 billion, 67.7% more than in 2023.

Financial Statements

News

There is no news available yet.